In this article, we will take a look at the Best Get Rich Fast Stocks to Buy Right Now.
In today’s fast-paced world, everyone is prioritising investments that have both high and relatively quick returns. The idea of getting “rich fast” is often met with skepticism, and for good reason, as many believe that sustainable wealth is built over time. However, sometimes markets present opportunities that, if seized, can translate into outsized returns in a short period. Such opportunities can be assessed through careful stock selection based on fundamentals, valuation, and upside potential.
While market discussions currently revolve around valuation concerns, some market participants still see drivers of healthy performance in 2026. According to a publication by JPMorgan, titled “2026 market outlook: A multidimensional polarization” and posted on December 09, 2025, the upcoming year will be shaped by the acceleration of AI, uneven monetary policy, and increasing market polarization. These, together with the continuously changing U.S. policy agenda, will define the global macro and market space. For 2026, the writer was bullish on global equities, anticipating double-digit returns across both developed markets (DM) and emerging markets (EM).
In the report, Dubravko Lakos-Bujas, Head of Global Markets Strategy, JPMorgan, stated:
“The AI-driven supercycle is fueling record capex and rapid earnings expansion. This momentum is spreading geographically and across a diverse list of industries, from technology and utilities to banks, healthcare and logistics, creating winners and losers in the process.”
With this outlook in mind, we have compiled a list of best get rich fast stocks to buy right now. These stocks primarily belong to the healthcare and technology sectors.
Source: Pexels
Our methodology
For this article, we considered stocks with a market capitalization between 300 million and 2 billion. Next, we filtered for stocks with a 5-year beta between 1.5 and 3 and an average daily volume over the last 20 trading days of over 1 million. We then shortlisted the thirteen companies with the highest upside potential and ranked them in ascending order. We also included data on hedge fund holdings in these companies based on Insider Monkey’s database, as of Q3 2025.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
13. Lexeo Therapeutics, Inc. (NASDAQ:LXEO)
Upside Potential as of December 24, 2025: 79.92%
Number of Hedge Fund Holders: 21
Share Price as of December 24, 2025: $10.56
As of December 24, Lexeo Therapeutics, Inc. (NASDAQ:LXEO) is a consensus buy from all eleven analysts covering the stock. While the target price ranges from $12 to $30, the median price target of $19 translates to an upside potential of 79.92%.
On December 18, Raymond James initiated coverage on Lexeo Therapeutics, Inc. (NASDAQ:LXEO) with a ‘Strong Buy’ rating and a price target of $25, citing solid results from two Phase 1/2 clinical trials and encouraging feedback from the FDA. With that said, the company’s lead candidate, LX2006, an AAV gene therapy for cardiomyopathy associated with Friedreich’s Ataxia, is “well-positioned for success” in its pivotal trial, the analyst asserted.
Raymond James expects the stock to gain momentum in 2026 following a finalized pivotal protocol with the FDA and initial proof of concept data on LX2020, an unmodeled gene therapy asset. The firm anticipates LX2006 revenue of $14.1 million in FY27, going as high as $805.3 million in FY32.
Earlier on December 10, Cantor Fitzgerald reaffirmed an ‘Overweight’ rating on Lexeo Therapeutics, Inc. (NASDAQ:LXEO), with a price target of $19. The reaffirmation, implying an upside potential of around 80%, is driven by the prospects of the company’s PKP2-ACM program. The analyst highlighted that the market remains focused on Lexeo’s Friedreich’s ataxia program and the PKP2-ACM program appears “under the radar,” particularly as the upcoming data expected in the next month could shift market perception.
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) is a New York-based clinical-stage genetic medicine company. Founded in 2017, the company has a pipeline of programs, including LX2006, LX2020, and LX2021.
12. Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)
Upside Potential as of December 24, 2025: 82.43%
Number of Hedge Fund Holders: 29
Share Price as of December 24, 2025: $13.43
According to TheFly, JonesResearch initiated coverage on Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) with a ‘Buy’ rating and set a price target of $61 on December 23, signaling an upside potential of 354.21% from the current price.
While anticipating “strong” clinical data from initial stages leading to positive Phase 3 results for lead asset MM120 in generalized anxiety disorder (GAD) and major depressive disorder (MDD), the firm believes Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) is well-positioned to benefit from ongoing trends that prioritize the development of psychedelic agents in psychiatry.
Although there are clinical and regulatory risks associated with its lead candidate due to the relation to LSD, the robust Phase III data will potentially result in regulatory approval, the firm concluded.
A day earlier, Patrick Trucchio, an analyst at H.C. Wainwright, reaffirmed a ‘Buy’ rating on Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), with an unchanged price target of $55. This translates to an upside potential of about 310%.
Overall, Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) is a consensus buy among all thirteen analysts covering the stock, as of December 24. With a median price target of $24.50, the stock exhibits an upside potential of 82.43%.
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) is a New York-based clinical-stage biopharmaceutical company specializing in novel treatments for brain health disorders. The company is dedicated to transforming how unmet needs like Anxiety Disorders and Depression are satisfied.
